Sotera Health Company (SHC)
NEUTRALFundamental
58
Precio
$19.54
Capitalización Bursátil
$5.48B
Parte 1 · Cuánto vale la empresa
Resumen
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.22B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$163M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$149M
Patrimonio Neto Total
$606M
Pasivo Total
$2.66B
Ratio de Liquidez
2.80
Cobertura de Intereses
-
Deuda/EBITDA
3.93
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$13.10
Precio Actual
$19.54
Margen de Seguridad
-49.1%
Rango de Valor Justo
$8.52 - $17.69
Métodos de Estimación
Métricas de Valoración
Ratio P/E
33.63
ROE
12.9%
Ratio P/B
8.22
P/FCF
48.54
Margen Bruto
55.0%
ROIC
-
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-
WACC
10.4%
ROIC − WACC
-
Criterios de Análisis Fundamental
Superado (13)
- EPS shows upward trend
- Gross Margin 55.0%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 20.6%
- Revenue Growth 5Y 7.3%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 8.4%
- Earnings Quality (OCF/NI) 1.79
- Net Margin Trend 13.4% vs 2.1%
- Piotroski F-Score 6/9
Fallido (9)
- Price CAGR -5.48%
- P/FCF 48.54
- P/B Ratio 8.22
- Debt/Equity ratio
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 4.0%
No disponible (5)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Michael B. Petras Jr. | Executive Chairman of the Board | 56 |
| Mr. Jonathan M. Lyons | Senior VP & CFO | 47 |
| Mr. Michael P. Rutz | President of Sterigenics U.S., LLC | 54 |
| Mr. Alton E. Shader | CEO & Director | 52 |
| Mr. Robert G. Hauzie | Chief Information Officer | - |
| Ms. Erika Ostrowski | Senior VP, General Counsel & Corporate Secretary | - |
| Ms. Kristin A. Gibbs | Chief Marketing Officer | - |
| Mr. William O. Lehmann Jr., J.D., M.B.A. | Senior Vice President of Strategy & Corporate Development | 59 |
| Ms. Sally R. Turner | Chief Human Resources Officer | - |
| Ms. Danielle J. Menture | Senior Vice President of Global Environmental, Health & Safety and Sustainability | - |
Riesgo de Auditoría
4
Riesgo del Consejo
7
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for SHC, sourced from Markets Gazette.
- 3/15/2026NEUTRALSotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
Sotera Health Company shares have seen an 18% increase over the past year, with recent activity indicating a significant stake trim by an insider amounting to $37 million. Sotera Health provides crucial sterilization and laboratory testing services to highly regulated industries globally, playing a vital role in maintaining essential supply chains. While the stock has performed well, the substantial insider sale could signal a divergence of opinion on future valuation or a need for liquidity, warranting investor attention.
- 3/2/2026NEGATIVESotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?
Sotera Health, a global provider of sterilization and laboratory solutions to the healthcare, pharmaceutical, and food industries, has seen an impressive 30% growth over the past year. Despite this robust performance, an unidentified fund divested $4 million worth of shares. This move raises questions among investors: why would an institutional entity sell such a significant stake in a rapidly growing company? It could signal strategic profit-taking, a portfolio rebalancing, or potentially a less optimistic view on the company's future prospects not yet apparent to the broader market. Investors should closely monitor upcoming developments and the rationale behind this significant divestment.
- 2/24/2026NEUTRALInsights into Sotera Health Q4 Earnings
Investors are keenly awaiting insights into Sotera Health's fourth-quarter earnings, a pivotal event for assessing the company's performance and future outlook. Analyzing quarterly results is crucial for understanding financial health, revenue growth, and profitability, all of which directly influence market sentiment and investment decisions. While specific details are yet to be disclosed, market focus remains on how Sotera Health navigated operational challenges and opportunities during the period. Key data points, such as revenue, earnings per share (EPS), and future guidance, will be scrutinized to identify trends and potential catalysts for the stock price. Results meeting or exceeding expectations could bolster confidence, whereas a disappointment might trigger a negative reaction.
via Markets Gazette